Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-03-29
Based on 364 first isolates · MED-B · Febrile UTI / pyelonephritis · 2025-03-30 → 2026-03-29
Internal medicine B
Per-organism detail: MED-B urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
ciprofloxacin 82 % (77 %–85 %)
Not covered: Enterococcus faecalis (7 %), Escherichia coli (4 %), Staphylococcus aureus (2 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
89 %
85 %
n = 26
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
83 %
81 %
n = 26
nitrofurantoin NIT
trend · Escherichia coli not for this site
83 %
85 %
n = 26
ciprofloxacin CIP
trend · Escherichia coli
82 %
73 %
n = 26
ceftriaxone CRO
trend · Escherichia coli
80 %
81 %
n = 26
mecillinam MEC
trend · Escherichia coli not for this site
80 %
85 %
n = 26
77 %
73 %
n = 26
trimethoprim TMP
trend · Escherichia coli not for this site
72 %
65 %
n = 26
45 %
46 %
n = 26
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
10 %
15 %
n = 26
4 %
0 %
n = 26
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
2 %
0 %
n = 26

Most likely organisms for this profile

Escherichia coli
58 %
Klebsiella pneumoniae
13 %
Enterococcus faecalis
7 %
Proteus mirabilis
7 %
Citrobacter freundii
5 %
Pseudomonas aeruginosa
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.